Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
96.62
+1.81 (1.91%)
Nov 21, 2024, 4:00 PM EST - Market closed
Blueprint Medicines Stock Forecast
Stock Price Forecast
The 19 analysts with 12-month price forecasts for Blueprint Medicines stock have an average target of 120.79, with a low estimate of 76 and a high estimate of 168. The average target predicts an increase of 25.02% from the current stock price of 96.62.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BPMC stock from 19 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 6 | 6 | 6 | 6 |
| Buy | 5 | 5 | 6 | 6 | 6 | 7 |
| Hold | 4 | 4 | 4 | 4 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 15 | 15 | 17 | 17 | 18 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Reiterates $125 | Buy | Reiterates | $125 | +29.37% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +39.72% | Nov 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $135 | Strong Buy | Reiterates | $135 | +39.72% | Nov 15, 2024 |
| JP Morgan | JP Morgan | Buy Initiates $126 | Buy | Initiates | $126 | +30.41% | Nov 14, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $153 → $151 | Buy | Maintains | $153 → $151 | +56.28% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
519.03M
from 249.38M
Increased by 108.13%
Revenue Next Year
720.98M
from 519.03M
Increased by 38.91%
EPS This Year
-1.00
from -8.37
EPS Next Year
-1.01
from -1.00
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 548.8M | 811.7M | 1.2B | ||
| Avg | 519.0M | 721.0M | 956.6M | ||
| Low | 493.4M | 560.7M | 744.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 120.1% | 56.4% | 63.9% | ||
| Avg | 108.1% | 38.9% | 32.7% | ||
| Low | 97.8% | 8.0% | 3.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.82 | 3.06 | 6.04 | ||
| Avg | -1.00 | -1.01 | 1.73 | ||
| Low | -1.20 | -2.78 | -1.22 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.